10-Q: AN2 Therapeutics Narrows Loss, Shifts Focus to Chagas & Oncology

AN2 Therapeutics reported a significant reduction in net loss and cash burn for Q2 2025, driven by strategic restructuring and the discontinuation of its MAC lung disease program, while advancing its Chagas and oncology pipelines.

Summary

• Net loss for the six months ended June 30, 2025, significantly decreased to $17.1 million, down from $31.1 million in the same period of 2024.
• Cash used in operating activities for the six months ended June 30, 2025, was $18.2 million, a substantial reduction from $32.0 million in the prior year period.
• Research and development expenses decreased by $15.9 million to $10.9 million for the six months ended June 30, 2025, primarily due to the termination of the EBO-301 trial and restructuring activities.
• The company discontinued the development of epetraborole for treatment-refractory MAC lung disease in May 2025 after the Phase 3 portion of the EBO-301 study did not meet its primary endpoint.
• Phase 1 start-up activities for AN2-502998 for chronic Chagas disease were initiated in May 2025, with the first Single Ascending Dose cohort dosing completed in August 2025.
• A collaboration with Drugs for Neglected Diseases initiative (DNDi) was announced in July 2025 to advance clinical development of AN2-502998 for Chagas disease.
• Discussions are underway with the U.S. government to fund Phase 2 development of epetraborole in acute melioidosis, following key insights from a completed observational trial.
• The NIAID contract for melioidosis was reduced by $9.0 million in June 2025, resulting in a total cumulative contract funding of up to $9.3 million, due to a U.S. Government cost efficiency initiative.
• The company anticipates advancing its first oncology compound into development later in 2025, with potential clinical proof of concept within the current cash runway, and a second oncology compound in 1H 2026.
• A workforce reduction of approximately 50% was implemented in August 2024, resulting in $2.2 million in severance and other charges.
• Cash, cash equivalents, and investments totaled $71.2 million as of June 30, 2025, with management believing this is sufficient to fund operations for at least 12 months from the filing date.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company significantly reduced its net loss and cash burn, this was largely due to the discontinuation of a key late-stage program (MAC lung disease), which is a major setback. The advancement of early-stage programs (Chagas, oncology) and new collaborations are positive, but these are still high-risk, long-term endeavors. The reduction in NIAID funding and the persistent material weaknesses in internal controls are also concerns. The 12-month cash runway indicates an upcoming need for further capital, adding to uncertainty.

Positives

• Net loss significantly reduced to $17.1 million for the six months ended June 30, 2025, compared to $31.1 million in the prior year.
• Cash used in operating activities decreased substantially to $18.2 million for the six months ended June 30, 2025, from $32.0 million in the prior year, indicating improved cash management.
• Research and development expenses saw a significant reduction of $15.9 million, primarily due to strategic restructuring and program termination.
• Initiation of Phase 1 start-up activities for AN2-502998 in chronic Chagas disease and completion of the first dosing cohort represent progress in a new pipeline area.
• Collaboration with DNDi for Chagas disease clinical development leverages external expertise and networks.
• Advancement of oncology programs is anticipated, with the first compound expected to enter development in 2025 and potential clinical proof of concept within the current cash runway.
• Increased reimbursement from funding arrangements, totaling $4.1 million for the six months ended June 30, 2025, compared to $1.0 million in the prior year.

Negatives

• Discontinuation of the epetraborole program for treatment-refractory MAC lung disease due to failure to meet the primary endpoint in the truncated Phase 3 study.
• Accumulated deficit increased to $222.9 million as of June 30, 2025, from $205.8 million at December 31, 2024.
• NIAID contract funding for melioidosis was reduced by $9.0 million to a cumulative total of $9.3 million due to a U.S. Government cost efficiency initiative.
• Interest income decreased by $1.5 million for the six months ended June 30, 2025, due to lower cash and investment balances and lower interest rates.
• General and administrative expenses slightly increased by $0.5 million for the six months ended June 30, 2025.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, and may never achieve or maintain profitability.
• Substantial additional funding is required to meet financial needs and pursue business objectives; failure to raise capital could delay or cease product development programs.
• Clinical trials of product candidates may fail to demonstrate safety and/or efficacy, leading to additional costs or delays in development and commercialization.
• Delays or difficulties in patient enrollment in clinical trials could impede clinical development and regulatory approvals.
• Reliance on single-source third parties for manufacturing product candidates increases the risk of insufficient quantities or unacceptable costs.
• Product candidates, if approved, may fail to achieve market acceptance by physicians, patients, and third-party payors.
• The company faces substantial competition from major pharmaceutical and biotechnology companies with greater resources.
• Material weaknesses in internal control over financial reporting persist, potentially affecting accurate and timely financial reporting.
• Rights to develop and commercialize technology are largely subject to terms and conditions of licenses from third parties, such as Anacor, and non-compliance could lead to loss of rights.
• Inability to obtain and maintain patent and other intellectual property protection could allow competitors to commercialize similar technologies.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval or limit commercial potential.
• Bacteria may develop resistance to antibacterial product candidates, affecting revenue potential.
• Macroeconomic uncertainties, including inflation and higher interest rates, may adversely impact business and operations.
• Disruptions at the FDA and other government agencies due to funding shortages or staffing limitations could hinder regulatory review and approval processes.
• Failure to obtain or maintain orphan drug designations could limit market exclusivity benefits.
• Failure to comply with reporting and payment obligations under U.S. governmental pricing programs could result in substantial liabilities.
• Relationships with healthcare professionals are subject to anti-kickback, fraud, and abuse laws, exposing the company to penalties.
• Changes in healthcare policies, laws, and regulations (e.g., Inflation Reduction Act, One Big Beautiful Bill Act) may impact the ability to commercialize products.
• Exposure to privacy and data security laws, rules, and regulations; non-compliance could harm the business.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws.
• Concentration of common stock ownership among existing executive officers, directors, and principal stockholders may prevent new investors from influencing corporate decisions.
• Sales of a substantial number of common stock shares may cause the price to decline.
• Provisions in corporate charter documents and Delaware law, and the adoption of a rights plan, could make an acquisition more difficult.
• Broad discretion in the use of cash, which may not increase investment value.
• No anticipated cash dividends; stockholders must rely on capital appreciation.
• Ability to use net operating loss carryforwards and other tax attributes may be limited.
• The trading price of common stock has been and may continue to be volatile.
• Significant disruptions of IT systems or cybersecurity incidents could result in harm.
• As an emerging growth company, reduced disclosure and governance requirements may make common stock less attractive to investors.
• Failure to adhere to Nasdaq listing requirements could result in delisting.
• Recent and potential future changes to U.S. and non-U.S. tax laws could adversely affect the company.
• Indemnity provisions in various agreements potentially expose the company to substantial liability.

Future Outlook

The company anticipates completing dosing in the Phase 1 study for AN2-502998 (Chagas disease) in the second half of 2025 and initiating a Phase 2 proof-of-concept study in 2026. It expects to advance its first oncology compound into development later in 2025, with potential clinical proof of concept within the current cash runway, and a second oncology compound in the first half of 2026. Discussions are ongoing with the U.S. government to fund Phase 2 development of epetraborole in acute melioidosis. The company is also actively exploring plans for an investigator-initiated study in M. abscessus, which could provide proof of concept and support future NDA-enabling trials. Management believes existing cash, cash equivalents, and investments are sufficient to fund operations for at least 12 months from the filing date, but substantial additional funding will be required thereafter.

Management Comments

• Management believes that its cash, cash equivalents, and investments as of June 30, 2025 will be sufficient to fund its current operating plan through at least 12 months from the issuance date of these condensed financial statements.
• We are committed to delivering high-impact drugs to patients that address critical medical needs and improve health outcomes.
• Discussions are underway with the U.S. government to fund Phase 2 development of epetraborole in acute melioidosis.
• We believe that our NTM clinical trials to date provide significant enabling data for epetraborole in M. abscessus and we are actively exploring plans for an investigator-initiated study in M. abscessus.
• The Company anticipates that, if this study moves forward, positive data could provide proof of concept in M. abscessus and support NDA-enabling future trials.
• We anticipate advancing the first oncology compound into development later this year with potential clinical proof of concept within the Companys current cash runway.
• We expect to advance our second oncology compound into development in the first half of 2026.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. AN2 Therapeutics' focus on boron chemistry platforms for infectious diseases (Chagas, melioidosis) and oncology aligns with industry trends seeking novel mechanisms of action for difficult-to-treat conditions. The discontinuation of a late-stage program (MAC lung disease) is a common occurrence in drug development, highlighting the inherent risks. The company's pivot and prioritization of other pipeline assets, coupled with a significant reduction in cash burn, reflect a strategic response to clinical trial outcomes and a focus on extending operational runway, a critical factor for clinical-stage biotechs. The pursuit of non-dilutive funding (NIAID, BMGF) is also a common strategy for smaller biotechs to manage capital needs.

Comparison to Industry Standards

• The discontinuation of the EBO-301 study for MAC lung disease, despite meeting a primary objective related to a PRO tool, but failing on sputum culture conversion, is a common outcome in drug development where efficacy endpoints are not met. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later-stage clinical trials even after promising early results.
• The company's cash runway of at least 12 months is typical for a clinical-stage biopharmaceutical company, but it necessitates future capital raises, a standard challenge in the industry.
• The company's reliance on third-party CROs and CMOs for preclinical, nonclinical, and clinical development, and manufacturing is a common industry practice, especially for smaller biotechs without in-house capabilities.
• The identified material weaknesses in internal control over financial reporting, particularly regarding accounting knowledge, segregation of duties, and IT general controls, are significant and indicate a need for substantial improvement to meet public company standards, which is a common challenge for companies transitioning from private to public status but requires diligent remediation.

Corporate Governance

Related Party Transactions

• MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP, whose managing director is Dr. Rob Readnour (a director of the company), adopted Rule 10b5-1 trading arrangements on April 17, 2025, for the sale of shares until August 15, 2026.

Stakeholder Impact

• Shareholders: Experience dilution from past equity raises and potential future capital raises. The discontinuation of the MAC lung disease program is a negative, but reduced cash burn and new program advancements offer future potential. Stock price volatility is a risk.
• Employees: A 50% workforce reduction in August 2024 impacted employees, potentially affecting morale and institutional knowledge. Remaining employees may face increased workloads.
• Customers/Patients: The discontinuation of the MAC lung disease program means epetraborole will not be available for that indication. New programs in Chagas and oncology offer future treatment possibilities for patients with high unmet needs.
• Creditors: Reduced cash burn and a 12-month cash runway provide some stability, but the need for future capital raises indicates ongoing financial risk.
• Suppliers/CROs/CMOs: Continued reliance on third parties for R&D and manufacturing, indicating ongoing business for these partners, but the reduction in R&D spend may impact some.

Next Steps

• Complete dosing in the Phase 1 study for AN2-502998 (Chagas disease) in the second half of 2025.
• Initiate a Phase 2 proof-of-concept study for AN2-502998 in 2026.
• Advance the first oncology compound into development later in 2025.
• Advance the second oncology compound into development in the first half of 2026.
• Continue discussions with the U.S. government to fund Phase 2 development of epetraborole in acute melioidosis.
• Actively explore plans for an investigator-initiated study of epetraborole in M. abscessus.

Key Dates

Recommendation

The company presents a mixed bag of results. The significant reduction in net loss and cash burn is a positive sign of improved financial discipline and extended operational runway, which is crucial for a clinical-stage biotech. However, this was largely achieved by discontinuing a late-stage program (MAC lung disease) due to a clinical trial failure, which is a major setback and indicates high development risk. While the company is strategically pivoting to advance its Chagas and oncology programs, these are still in early stages and carry substantial clinical and regulatory uncertainties. The reduction in NIAID funding for melioidosis is also a negative. The persistent material weaknesses in internal controls are a governance concern. Given the high-risk nature of biotech, the recent program failure, and the need for future capital, a 'Hold' recommendation is appropriate. Investors should monitor the progress of the Chagas and oncology programs and the company's ability to secure additional funding, as these will be critical determinants of future value.

Keywords

Biopharmaceutical, Drug development, Chagas disease, Melioidosis, Oncology, Clinical trials, SEC filing, 10-Q, Biotech, Drug discovery, Boron chemistry, Rare diseases, Infectious diseases, AN2-502998, Epetraborole, Financial results, Cash runway, Regulatory approval, Intellectual property